Avodart Cost in Michigan 2026: Dutasteride Prices, Insurance, and Compounding

What Does Avodart Actually Cost in Michigan in 2026?

Brand-name Avodart (dutasteride 0.5 mg, GSK) carries a manufacturer list price near $290 per month. Almost nobody pays that. Generic dutasteride 0.5 mg capsules are available at Michigan retail pharmacies for approximately $25 per month cash-pay in 2026, representing an 89% reduction from brand list price. The gap between those two numbers is the central fact every Michigan patient needs to know before filling a prescription.

Brand Avodart vs. Generic Dutasteride

Generic dutasteride has been available in the United States since 2015 following patent expiration. The FDA's bioequivalence standard requires generic formulations to deliver 80 to 125 percent of the reference drug's active ingredient exposure, and all approved generics for dutasteride meet that bar. The FDA's Orange Book lists currently approved dutasteride generics.

Therapeutically, switching from brand Avodart to a generic is not a clinical step down. The FDA confirmed bioequivalence, and the Avodart prescribing information applies equally to all approved formulations at the same 0.5 mg dose.

Real Michigan Pharmacy Cash Prices (2026 Estimates)

Prices vary by chain, zip code, and whether a discount card is applied. The $25/month figure reflects the national GoodRx low range verified at Michigan-area pharmacies. Without a discount card, the same 30-capsule supply at some independent pharmacies may run $60 to $90. Patients who present a free GoodRx, RxSaver, or NeedyMeds card at checkout typically land in the $20 to $35 range statewide. GoodRx pricing methodology is publicly described.

Walmart and Costco pharmacies in Michigan have historically offered generic dutasteride at or below the $25 threshold without a third-party card due to in-house generic pricing programs. Calling ahead with the GoodRx coupon code is the single fastest way to confirm the lowest price at any specific Michigan ZIP code.

Michigan Medicaid Coverage for Dutasteride

Michigan Medicaid (Healthy Michigan Plan and traditional Medicaid) covers generic dutasteride for benign prostatic hyperplasia (BPH) under the Michigan Department of Health and Human Services (MDHHS) pharmacy benefit, but a prior authorization (PA) is required. The MDHHS Medicaid pharmacy policy manual outlines covered drug classes and PA criteria.

Prior Authorization Requirements

PA for dutasteride under Michigan Medicaid typically requires documentation that the patient has a confirmed BPH diagnosis, along with evidence that alpha-blocker monotherapy (for example, tamsulosin) was tried for at least 30 days without adequate symptom control, or that combination therapy is clinically indicated per American Urological Association guidelines. AUA guidelines on BPH management are the recognized clinical standard for PA justification.

Your prescriber completes the PA form; most Michigan Medicaid managed care plans process PA requests within 3 business days. If denied, a peer-to-peer appeal between your physician and the plan medical director resolves most cases.

Off-Label Use (Hair Loss) and Medicaid

Michigan Medicaid does not cover dutasteride for androgenic alopecia (male pattern hair loss). Off-label prescribing is legal, but Medicaid reimbursement for non-FDA-approved indications requires explicit listing on Michigan's Medicaid covered outpatient drug file, and androgenic alopecia is not listed. Patients seeking dutasteride for hair loss under Medicaid must pay cash or use a discount card.

The clinical rationale for dutasteride in hair loss is supported by peer-reviewed evidence: Eun et al. (J Am Acad Dermatol, 2010; N=153) demonstrated that dutasteride 0.5 mg produced significantly greater increases in total and target-area hair counts at 24 weeks compared with finasteride 1 mg (P<0.001), and hair weight also favored dutasteride. Full data: PubMed PMID 20691790. Despite that evidence, payer coverage for cosmetic indications remains narrow.

Insurance Coverage for Avodart in Michigan: Commercial Plans

Most Michigan commercial insurers, including Blue Cross Blue Shield of Michigan, Priority Health, McLaren Health Plan, and Molina Healthcare of Michigan, tier dutasteride on formulary. Generic dutasteride appears on Tier 1 or Tier 2 on the majority of Michigan Exchange and employer plans, meaning copays run $10 to $45 per month after deductible. Brand Avodart, where listed at all, sits on Tier 3 or Tier 4 with 30 to 50% coinsurance, often making generic the default dispensed product.

Verifying Your Specific Plan

Three steps confirm your out-of-pocket cost before the pharmacy:

1. Log into your insurer's online formulary tool and search "dutasteride 0.5 mg capsule."
2. Note the tier, any PA or step-therapy requirement, and the quantity limit (most plans allow 30 capsules per 30-day supply).
3. Ask your prescriber to write the prescription for generic dutasteride rather than brand Avodart to prevent automatic Tier 3 billing.

CMS explains how formulary tiers affect cost-sharing. The same tier logic applies to Michigan ACA marketplace plans.

Medicare Part D in Michigan

Dutasteride for BPH is covered under most Michigan Medicare Part D plans. The 2026 Medicare Part D out-of-pocket cap of $2,000 (established by the Inflation Reduction Act) applies to all Part D covered drugs, including dutasteride, after which the plan pays 100%. CMS 2026 Part D fact sheet confirms the $2,000 annual cap. For a drug costing $25 to $45 per month, most patients will not reach that cap on dutasteride alone, but it matters for patients taking multiple Part D medications.

Compounded Dutasteride in Michigan: Legality and Cost

Compounded dutasteride is legal in Michigan when dispensed by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. The cost is approximately $40 per month for typical topical or oral compounded formulations, which is higher than generic tablets at cash price but allows for custom dosing, combination formulations, or topical delivery routes not available in FDA-approved products.

Federal 503A Framework

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs for individual patients when several conditions are met: a valid prescription exists, the drug is not on the FDA's "Demonstrably Difficult to Compound" list, and the pharmacy is state-licensed and compliant with USP standards. FDA's 503A compounding guidance describes these requirements in detail. Dutasteride is not on the FDA's list of drugs withdrawn from the market for safety reasons, so 503A compounding of dutasteride is federally permissible.

Michigan State Law

The Michigan Board of Pharmacy regulates 503A compounding pharmacies under the Michigan Public Health Code (Act 368 of 1978). A Michigan-licensed 503A pharmacy may legally fill a compounded dutasteride prescription for a Michigan patient. Patients should confirm the pharmacy holds an active Michigan license by checking the Michigan Department of Licensing and Regulatory Affairs (LARA) license lookup. An out-of-state 503A pharmacy may also ship to Michigan patients if it holds a Michigan non-resident pharmacy license.

Topical vs. Oral Compounded Formulations

Most 503A pharmacies offer dutasteride in two main forms:

• Oral capsules or solution: Allows flexible dosing (for example, 0.5 mg or 2.5 mg doses used in some hair-loss protocols).
• Topical solution or gel: Applied directly to the scalp; studied in androgenic alopecia research, though the FDA has not approved any topical dutasteride product. A randomized controlled trial published in the Journal of the American Academy of Dermatology found topical dutasteride superior to topical finasteride for hair counts in men with androgenic alopecia. PubMed PMID 33279347.

Compounded formulations are not bioequivalent substitutes for FDA-approved Avodart and carry no FDA efficacy or safety approval. Your prescriber and a licensed pharmacist should discuss which formulation suits your clinical situation.

Telehealth Access to Dutasteride in Michigan

Telehealth prescribing of dutasteride is legal in Michigan. A Michigan-licensed prescriber may evaluate a patient via synchronous video or, depending on platform and clinical situation, asynchronous questionnaire, and issue a valid prescription for dutasteride without an in-person visit, provided the prescriber establishes a valid patient-provider relationship under Michigan law. Michigan's telehealth statute (MCL 333.16171) does not require an in-person prior visit for most prescription medications.

What a Michigan Telehealth Visit for Dutasteride Involves

A typical telehealth evaluation for BPH or androgenic alopecia takes 10 to 20 minutes and covers:

• Symptom history (International Prostate Symptom Score for BPH; Ludwig or Norwood-Hamilton scale review for hair loss)
• PSA status and baseline labs if not recently drawn
• Contraindications: dutasteride is contraindicated in pregnancy and in women of childbearing potential due to teratogenic risk to male fetuses (FDA label)
• Current medications (particularly PDE5 inhibitors, alpha-blockers, and CYP3A4 inhibitors that affect dutasteride metabolism)

After evaluation, the prescriber sends the prescription electronically to any Michigan retail pharmacy or a licensed 503A compounding pharmacy. The patient fills it locally or via mail.

Telehealth Platforms Active in Michigan

Multiple national telehealth platforms with Michigan-licensed physicians offer dutasteride prescriptions for BPH and hair loss. HealthRX provides a Michigan-compliant telehealth pathway for dutasteride evaluation, with prescriptions routed to the patient's preferred pharmacy or a vetted 503A partner. CMS telehealth policy updates for 2026 confirm continued coverage of telehealth visits under Medicare and Medicaid where applicable.

The Cheapest Legal Path to Dutasteride in Michigan

The decision framework below organizes Michigan patients by insurance status and clinical indication to identify the lowest net cost route.

Step 1. Confirm your indication. BPH patients with Michigan Medicaid should pursue the PA pathway first; typical copay after PA approval runs $0 to $3 per month. BPH patients with commercial insurance should verify Tier 1 or Tier 2 generic coverage before filling. Hair-loss patients on any public insurance plan will pay cash.

Step 2. Run a discount card comparison. Patients paying cash should run the same quantity (30 capsules, dutasteride 0.5 mg) through GoodRx, RxSaver, and Blink Health simultaneously. At major Michigan chains in early 2025, the lowest verified price was $18.62 for 30 capsules at Walmart using a GoodRx coupon. Prices change monthly.

Step 3. Consider 90-day fills. Most Michigan pharmacy chains and mail-order services offer a 90-day supply discount. A 90-day generic fill often costs $55 to $70 rather than $75 ($25 x 3), saving approximately $5 to $20 per quarter.

Step 4. Assess compounding only for clinical reasons, not cost. Compounded dutasteride at $40/month costs more than generic tablets at $25/month. Compounding is appropriate when a patient needs a non-standard dose, a topical route, or a combination formulation unavailable commercially. Cost alone is not a reason to choose compounding over the FDA-approved generic.

Step 5. Check manufacturer and charitable programs. GSK offers a savings card for brand Avodart for commercially insured patients (not valid for Medicaid or Medicare). The GSK patient assistance program may cover brand Avodart for uninsured patients meeting income criteria. NeedyMeds and RxAssist maintain updated lists of manufacturer assistance programs. NeedyMeds dutasteride page.

Clinical Background: Why Dutasteride Is Prescribed

Dutasteride is a dual 5-alpha-reductase inhibitor. It blocks both Type I and Type II isoenzymes of 5-alpha-reductase, suppressing conversion of testosterone to dihydrotestosterone (DHT) by more than 90% at steady state. Finasteride, by contrast, blocks only Type II and suppresses DHT by approximately 70%. FDA pharmacology review for dutasteride documents this dual-inhibition mechanism.

FDA-Approved Indications

The FDA approved dutasteride (Avodart) in 2001 for treatment of symptomatic BPH in men with an enlarged prostate. A combination capsule (dutasteride 0.5 mg plus tamsulosin 0.4 mg, sold as Jalyn) received FDA approval in 2010 for BPH. FDA Jalyn approval. The COMBAT trial (N=4,844) showed combination dutasteride plus tamsulosin reduced the risk of clinical BPH progression by 44% compared with tamsulosin alone over 48 months. PubMed PMID 20042541.

Off-Label Use in Androgenic Alopecia

Dutasteride 0.5 mg daily is prescribed off-label for male androgenic alopecia. The evidence base includes multiple randomized controlled trials. Eun et al. (J Am Acad Dermatol, 2010; N=153) showed dutasteride 0.5 mg significantly outperformed finasteride 1 mg on total hair count at 24 weeks (P<0.001). PubMed PMID 20691790. A 2019 network meta-analysis in the Journal of the European Academy of Dermatology and Venereology ranked dutasteride 0.5 mg as the most effective oral 5-alpha-reductase inhibitor for hair count improvement. PubMed PMID 31347239.

Despite this evidence, the FDA has not approved dutasteride for androgenic alopecia. Prescribers may legally prescribe it off-label, and patients may legally fill those prescriptions, but insurance coverage for hair loss remains limited.

Safety and Monitoring

Dutasteride carries a Pregnancy Category X label. FDA teratogenicity data show the drug can cause ambiguous genitalia in male fetuses exposed in utero. Men taking dutasteride should not donate blood for at least 6 months after stopping, per FDA guidance, to prevent inadvertent exposure to pregnant recipients. Baseline PSA should be drawn before starting; dutasteride lowers PSA by approximately 50% at 6 months, requiring the measured value to be doubled for meaningful cancer-screening interpretation. AUA early detection guideline for prostate cancer addresses this PSA adjustment.

Sexual side effects (decreased libido, ejaculation disorders, erectile dysfunction) occur in approximately 3 to 7% of men in clinical trials and are reversible upon discontinuation in most cases. NEJM COMBAT-related safety data.

Dutasteride Dosing and Administration in Michigan Prescriptions

The standard FDA-approved dose is 0.5 mg orally once daily. Capsules should be swallowed whole; dutasteride is absorbed through the skin and mucous membranes, so broken or chewed capsules expose others (including women and children) to the drug. No dose adjustment is required for renal impairment. Hepatic impairment requires caution; dutasteride is extensively metabolized by CYP3A4 and CYP3A5.

Steady-state DHT suppression takes approximately 1 to 3 months. Symptomatic BPH improvement may take 3 to 6 months of continuous use. Hair density improvements in androgenic alopecia become visible at 6 to 12 months in most trial participants. Long-term efficacy data from the 4-year REDUCE trial show continued benefit with sustained use. Stopping dutasteride results in DHT returning to baseline within 12 weeks and symptom recurrence in BPH and hair loss over 6 to 12 months.